WO2004108114A3 - Composition antifongique et son procede de fabrication - Google Patents

Composition antifongique et son procede de fabrication Download PDF

Info

Publication number
WO2004108114A3
WO2004108114A3 PCT/IN2004/000076 IN2004000076W WO2004108114A3 WO 2004108114 A3 WO2004108114 A3 WO 2004108114A3 IN 2004000076 W IN2004000076 W IN 2004000076W WO 2004108114 A3 WO2004108114 A3 WO 2004108114A3
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
manufacture
triazole
derivatives
preparation
Prior art date
Application number
PCT/IN2004/000076
Other languages
English (en)
Other versions
WO2004108114A2 (fr
WO2004108114B1 (fr
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Original Assignee
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani filed Critical Dinesh Shantilal Patel
Publication of WO2004108114A2 publication Critical patent/WO2004108114A2/fr
Publication of WO2004108114A3 publication Critical patent/WO2004108114A3/fr
Publication of WO2004108114B1 publication Critical patent/WO2004108114B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

L'invention concerne une composition pharmaceutique comprenant au moins un agent antifongique choisi dans le groupe imidazoles, triazoles, allylamines, leurs dérivés et polyènes, divers composés tels que hydroxy pyridones comme 2,5(1'S,6'R)-7-chloro-2',-4,6-triméthoxy-6'-méthylspiro[benzofurane-2(3H),1'-[2]cyclohexène]-3,4'-dione et acide carbamothioïque-méthyl(3-méthylphényl) O-2-naphthalényl ester, en particulier, α-(2,4-Difluorophényl)- α-(1H-1,2,4-triazole-1-ylméthyl)-1H-1,2,4-triazole-1-éthanol et N-[(2E)-6,6-Diméthyl-2-hepten-4-ynyl]-N-méthyl-1-naphthalène-méthanamine hydrochlorure dans un support sélectif de 2,5-di-O-méthyl-1,4:3,6-dianhydro-D-glucitol et ses dérivés. La préparation est appropriée pour administration par voies parentérale, orale et locale. La préparation en solution peut être administrée directement ou utilisée pour fabriquer des comprimés, des suspensions, des gouttes, des formulations de vernis à ongles et analogues.
PCT/IN2004/000076 2003-03-31 2004-03-31 Composition antifongique et son procede de fabrication WO2004108114A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN49MU2003 2003-03-31
IN49/MUM/2003 2003-03-31

Publications (3)

Publication Number Publication Date
WO2004108114A2 WO2004108114A2 (fr) 2004-12-16
WO2004108114A3 true WO2004108114A3 (fr) 2005-10-06
WO2004108114B1 WO2004108114B1 (fr) 2005-11-17

Family

ID=33495852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000076 WO2004108114A2 (fr) 2003-03-31 2004-03-31 Composition antifongique et son procede de fabrication

Country Status (1)

Country Link
WO (1) WO2004108114A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002026A1 (es) * 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
EP0156507A1 (fr) * 1984-02-23 1985-10-02 Ortho Pharmaceutical Corporation Solution antifongique dermatologique
EP0230226A2 (fr) * 1986-01-15 1987-07-29 Kali-Chemie Pharma GmbH Emulsions antimycosiques
EP0270316A2 (fr) * 1986-12-04 1988-06-08 Pfizer Inc. Compositions topiques contenant des imidazoles 1-substitués et des agents non-steroides anti-inflammatoires pour le traitement de l'acné
WO1989005143A1 (fr) * 1986-08-04 1989-06-15 Research Corporation Technologies, Inc. Procede de traitement d'affections cutanees
WO1991002518A1 (fr) * 1989-08-25 1991-03-07 Bioglan Laboratories Ltd. Preparations pharmaceutiques et appareil en permettant l'administration
WO1993015719A1 (fr) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Formulations d'itraconazole liposomiques
WO1997017075A1 (fr) * 1995-11-08 1997-05-15 Pierre Fabre Medicament Composition pharmaceutique topique moussante pour le traitement des dermatoses, induites par pityrosporum ovale
US6455592B1 (en) * 1991-03-08 2002-09-24 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
EP0156507A1 (fr) * 1984-02-23 1985-10-02 Ortho Pharmaceutical Corporation Solution antifongique dermatologique
EP0230226A2 (fr) * 1986-01-15 1987-07-29 Kali-Chemie Pharma GmbH Emulsions antimycosiques
WO1989005143A1 (fr) * 1986-08-04 1989-06-15 Research Corporation Technologies, Inc. Procede de traitement d'affections cutanees
EP0270316A2 (fr) * 1986-12-04 1988-06-08 Pfizer Inc. Compositions topiques contenant des imidazoles 1-substitués et des agents non-steroides anti-inflammatoires pour le traitement de l'acné
WO1991002518A1 (fr) * 1989-08-25 1991-03-07 Bioglan Laboratories Ltd. Preparations pharmaceutiques et appareil en permettant l'administration
US6455592B1 (en) * 1991-03-08 2002-09-24 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
WO1993015719A1 (fr) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Formulations d'itraconazole liposomiques
WO1997017075A1 (fr) * 1995-11-08 1997-05-15 Pierre Fabre Medicament Composition pharmaceutique topique moussante pour le traitement des dermatoses, induites par pityrosporum ovale

Also Published As

Publication number Publication date
WO2004108114A2 (fr) 2004-12-16
WO2004108114B1 (fr) 2005-11-17

Similar Documents

Publication Publication Date Title
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
DK0783501T3 (da) Pyrimidonderivater med anti-fungal aktivitet
HUP0204519A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
CA2400268A1 (fr) Derives de pyrrolopyrimidinone, procedes d'elaboration et d'utilisation
AP1760A (en) Platinum derivative pharmaceutical formulations.
IL114894A (en) Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
HUP0303722A3 (en) Urea derivatives as integrin alpha 4 antanists, process for their preparation and pharmaceutical compositions containing them
HUP0101581A3 (en) Pyrazole derivatives as p-38 map kinase inhibitors, the pharmaceutical compositions containing the same, process for their preparation and their use
ATE316083T1 (de) Adamantanderivate
MA27080A1 (fr) Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US20220387611A1 (en) Methods for treating cancer
WO2003053945A3 (fr) Nouveaux composes
PT1230236E (pt) Composto com propriedades de libertacao de hormonas de crescimento
GB0109122D0 (en) Novel compounds
HUP0200281A3 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them
EP2210643A3 (fr) Combinaisons comprenants des épothilones et leurs utilisations pharmaceutiques
WO2004108114A3 (fr) Composition antifongique et son procede de fabrication
WO2005013935A3 (fr) Nouvelle composition
IL148573A0 (en) New pyrimidine -2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
DE60200041D1 (de) Indenoindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
WO2001004112A3 (fr) Derives de benzofuran
DE60205239D1 (de) Azol- oder triazol-derivate, verfahren zu deren herstellung und ihre verwendung als antifungale arzneimittel
AU2003284769A1 (en) 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050923

122 Ep: pct application non-entry in european phase